Proteins > Broad substrate specificity ATP-binding cassette transporter ABCG2
Page last updated: 2024-08-07 18:53:26
Broad substrate specificity ATP-binding cassette transporter ABCG2
A broad substrate specificity ATP-binding cassette transporter ABCG2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9UNQ0]
Synonyms
EC 7.6.2.2;
ATP-binding cassette sub-family G member 2;
Breast cancer resistance protein;
CDw338;
Mitoxantrone resistance-associated protein;
Placenta-specific ATP-binding cassette transporter;
Urate exporter
Research
Bioassay Publications (72)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 16 (22.22) | 29.6817 |
2010's | 44 (61.11) | 24.3611 |
2020's | 12 (16.67) | 2.80 |
Compounds (151)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
b 844-39 | Homo sapiens (human) | IC50 | 6.1000 | 1 | 1 |
benzbromarone | Homo sapiens (human) | IC50 | 0.2000 | 1 | 1 |
beta-naphthoflavone | Homo sapiens (human) | IC50 | 7.1850 | 2 | 2 |
caffeine | Homo sapiens (human) | IC50 | 14,000.0000 | 1 | 1 |
verapamil | Homo sapiens (human) | IC50 | 192.0001 | 3 | 3 |
candesartan cilexetil | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
cl 387785 | Homo sapiens (human) | IC50 | 0.2000 | 1 | 1 |
clofazimine | Homo sapiens (human) | IC50 | 3.2000 | 1 | 1 |
dipyridamole | Homo sapiens (human) | IC50 | 6.4000 | 1 | 1 |
fenofibrate | Homo sapiens (human) | IC50 | 5.1000 | 1 | 1 |
furosemide | Homo sapiens (human) | IC50 | 3.2000 | 1 | 1 |
glyburide | Homo sapiens (human) | IC50 | 150.0000 | 2 | 2 |
itraconazole | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
lansoprazole | Homo sapiens (human) | IC50 | 14.4000 | 1 | 1 |
losartan | Homo sapiens (human) | IC50 | 35.0000 | 1 | 1 |
mitoxantrone | Homo sapiens (human) | IC50 | 0.9038 | 1 | 1 |
nicardipine | Homo sapiens (human) | IC50 | 10.6980 | 2 | 2 |
nifedipine | Homo sapiens (human) | IC50 | 50.5000 | 1 | 1 |
nimodipine | Homo sapiens (human) | IC50 | 13.7000 | 1 | 1 |
nitrendipine | Homo sapiens (human) | IC50 | 21.1000 | 1 | 1 |
omeprazole | Homo sapiens (human) | IC50 | 17.6000 | 1 | 1 |
pantoprazole | Homo sapiens (human) | IC50 | 7.7500 | 2 | 2 |
pd 153035 | Homo sapiens (human) | IC50 | 2.0250 | 2 | 2 |
rabeprazole | Homo sapiens (human) | IC50 | 8.5000 | 1 | 1 |
imatinib | Homo sapiens (human) | IC50 | 2.9096 | 6 | 6 |
sulfasalazine | Homo sapiens (human) | IC50 | 0.4600 | 1 | 1 |
thioridazine | Homo sapiens (human) | IC50 | 6.6000 | 1 | 1 |
delavirdine | Homo sapiens (human) | IC50 | 18.7000 | 1 | 1 |
reserpine | Homo sapiens (human) | IC50 | 16.9009 | 3 | 3 |
estrone | Homo sapiens (human) | IC50 | 6.5000 | 2 | 2 |
1,3-benzodioxole | Homo sapiens (human) | IC50 | 0.9400 | 1 | 1 |
flavone | Homo sapiens (human) | IC50 | 21.5000 | 2 | 2 |
alpha-naphthoflavone | Homo sapiens (human) | IC50 | 1.3550 | 2 | 2 |
diltiazem | Homo sapiens (human) | IC50 | 851.1380 | 1 | 1 |
mefloquine | Homo sapiens (human) | IC50 | 18.0000 | 1 | 1 |
topotecan | Homo sapiens (human) | IC50 | 0.1700 | 1 | 1 |
atorvastatin | Homo sapiens (human) | IC50 | 4.3000 | 1 | 1 |
efavirenz | Homo sapiens (human) | IC50 | 20.6000 | 1 | 1 |
nelfinavir | Homo sapiens (human) | IC50 | 12.5000 | 2 | 2 |
amprenavir | Homo sapiens (human) | IC50 | 181.0000 | 1 | 1 |
telmisartan | Homo sapiens (human) | IC50 | 16.9000 | 1 | 1 |
tangeretin | Homo sapiens (human) | IC50 | 18.0000 | 2 | 2 |
nobiletin | Homo sapiens (human) | IC50 | 4.6500 | 2 | 2 |
vexibinol | Homo sapiens (human) | IC50 | 2.2050 | 2 | 2 |
pinostrobin | Homo sapiens (human) | IC50 | 19.9500 | 2 | 2 |
atovaquone | Homo sapiens (human) | IC50 | 0.2300 | 1 | 1 |
5,7-dimethoxyflavone | Homo sapiens (human) | IC50 | 10.1000 | 2 | 2 |
lopinavir | Homo sapiens (human) | IC50 | 7.6000 | 1 | 1 |
3,5,7,3',4'-pentamethoxyflavone | Homo sapiens (human) | IC50 | 1.3510 | 2 | 2 |
6-methoxyflavanone | Homo sapiens (human) | IC50 | 32.5000 | 2 | 2 |
sn 38 | Homo sapiens (human) | IC50 | 0.1760 | 1 | 1 |
elacridar | Homo sapiens (human) | IC50 | 0.2852 | 7 | 7 |
gefitinib | Homo sapiens (human) | IC50 | 1.2900 | 5 | 5 |
febuxostat | Homo sapiens (human) | IC50 | 0.0270 | 1 | 1 |
sinensetin | Homo sapiens (human) | IC50 | 8.6500 | 2 | 2 |
3-methoxyflavone | Homo sapiens (human) | IC50 | 1.2450 | 2 | 2 |
6-methoxyflavone | Homo sapiens (human) | IC50 | 6.7000 | 2 | 2 |
atazanavir | Homo sapiens (human) | IC50 | 69.1000 | 1 | 1 |
tariquidar | Homo sapiens (human) | IC50 | 1.2363 | 12 | 12 |
3,3',4',5,6,7,8-heptamethoxyflavone | Homo sapiens (human) | IC50 | 1.5000 | 2 | 2 |
erlotinib | Homo sapiens (human) | IC50 | 25.0650 | 2 | 2 |
scutellarin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
etravirine | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
lapatinib | Homo sapiens (human) | IC50 | 3.2000 | 1 | 1 |
sorafenib | Homo sapiens (human) | IC50 | 3.1000 | 1 | 1 |
3',4'-dimethoxy-alpha-naphthoflavone | Homo sapiens (human) | IC50 | 1.1800 | 2 | 2 |
5-Hydroxy-7-methoxy-6-methylflavone | Homo sapiens (human) | IC50 | 2.9000 | 2 | 2 |
5,7-dimethoxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one | Homo sapiens (human) | IC50 | 24.5000 | 2 | 2 |
ritonavir | Homo sapiens (human) | IC50 | 19.5000 | 1 | 1 |
tryptoquivaline | Homo sapiens (human) | IC50 | 1.5899 | 12 | 12 |
tryptoquivaline | Homo sapiens (human) | Ki | 1.3000 | 1 | 1 |
1-methoxy-10H-acridin-9-one | Homo sapiens (human) | IC50 | 6.3000 | 1 | 1 |
saquinavir | Homo sapiens (human) | IC50 | 19.5000 | 2 | 2 |
abacavir | Homo sapiens (human) | IC50 | 385.0000 | 1 | 1 |
6-prenylchrysin | Homo sapiens (human) | IC50 | 0.2900 | 2 | 2 |
tacrolimus | Homo sapiens (human) | IC50 | 3.3000 | 1 | 1 |
diethylstilbestrol | Homo sapiens (human) | IC50 | 0.5000 | 2 | 2 |
ketoconazole | Homo sapiens (human) | IC50 | 15.3000 | 1 | 1 |
posaconazole | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
micafungin | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
8-prenylnaringenin | Homo sapiens (human) | IC50 | 3.1000 | 1 | 1 |
s 1033 | Homo sapiens (human) | IC50 | 2.5000 | 1 | 1 |
N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine | Homo sapiens (human) | IC50 | 1.2450 | 2 | 2 |
diethylstilbestrol dipropionate | Homo sapiens (human) | IC50 | 3.0000 | 2 | 2 |
chlorprothixene | Homo sapiens (human) | IC50 | 42.0000 | 1 | 1 |
curcumin | Homo sapiens (human) | IC50 | 1.6300 | 1 | 1 |
N-{3-[(2-phenylquinazolin-4-yl)amino]phenyl}acetamide | Homo sapiens (human) | IC50 | 0.2510 | 2 | 2 |
cancidas | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
fusidic acid | Homo sapiens (human) | IC50 | 52.0000 | 1 | 1 |
dasatinib | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
zd 6474 | Homo sapiens (human) | IC50 | 0.2000 | 1 | 1 |
sq 109 | Homo sapiens (human) | IC50 | 5.5000 | 1 | 1 |
quercetin | Homo sapiens (human) | IC50 | 7.2500 | 2 | 2 |
apigenin | Homo sapiens (human) | IC50 | 8.3333 | 3 | 3 |
luteolin | Homo sapiens (human) | IC50 | 8.9000 | 1 | 1 |
ayanin | Homo sapiens (human) | IC50 | 2.2800 | 3 | 3 |
kaempferol | Homo sapiens (human) | IC50 | 5.4500 | 2 | 2 |
harmine | Homo sapiens (human) | GI50 | 1.6700 | 3 | 3 |
harmine | Homo sapiens (human) | IC50 | 5.0800 | 1 | 1 |
genistein | Homo sapiens (human) | IC50 | 7.8500 | 2 | 2 |
amphotericin b | Homo sapiens (human) | IC50 | 127.0000 | 1 | 1 |
chrysin | Homo sapiens (human) | IC50 | 2.0500 | 2 | 2 |
morin | Homo sapiens (human) | IC50 | 35.0000 | 2 | 2 |
pachypodol | Homo sapiens (human) | IC50 | 17.2000 | 1 | 1 |
l 660,711 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
tectochrysin | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
cyclosporine | Homo sapiens (human) | IC50 | 24.6546 | 3 | 3 |
cyclosporine | Homo sapiens (human) | Ki | 0.5000 | 1 | 1 |
sirolimus | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
topiroxostat | Homo sapiens (human) | IC50 | 0.1800 | 1 | 1 |
licochalcone a | Homo sapiens (human) | IC50 | 2.2717 | 24 | 24 |
5,4'-dihydroxy-3,6,7-trimethoxyflavone | Homo sapiens (human) | IC50 | 1.6000 | 2 | 2 |
bosutinib | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
su 11248 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
5-hydroxy-3,3',4',7-tetramethoxyflavone | Homo sapiens (human) | IC50 | 0.6000 | 4 | 4 |
flavokawain a | Homo sapiens (human) | IC50 | 4.4150 | 2 | 2 |
Isoliquiritigenin 4,4'-dimethyl ether | Homo sapiens (human) | IC50 | 3.2000 | 2 | 2 |
3,3',4,5'-tetramethoxy-trans-stilbene | Homo sapiens (human) | IC50 | 0.1600 | 2 | 2 |
2-chloro-4',6'-dimethoxy-2'-hydroxychalcone | Homo sapiens (human) | IC50 | 4.0450 | 2 | 2 |
metochalcone | Homo sapiens (human) | IC50 | 2.1250 | 2 | 2 |
proguanil | Homo sapiens (human) | IC50 | 118.0000 | 1 | 1 |
rilpivirine | Homo sapiens (human) | IC50 | 1.5000 | 1 | 1 |
sophoraflavanone a | Homo sapiens (human) | IC50 | 12.3000 | 1 | 1 |
isavuconazole | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
timcodar | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
tivozanib | Homo sapiens (human) | IC50 | 0.0700 | 1 | 1 |
ko 143 | Homo sapiens (human) | GI50 | 0.5403 | 3 | 3 |
ko 143 | Homo sapiens (human) | IC50 | 0.1882 | 41 | 41 |
regorafenib | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
alisporivir | Homo sapiens (human) | IC50 | 2.5000 | 1 | 1 |
fostamatinib | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
wk-x-34 | Homo sapiens (human) | IC50 | 1.2931 | 3 | 3 |
xr 9577 | Homo sapiens (human) | IC50 | 0.7516 | 11 | 11 |
gdc 0449 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
bms 754807 | Homo sapiens (human) | IC50 | 10.2000 | 1 | 1 |
ponatinib | Homo sapiens (human) | IC50 | 0.0400 | 1 | 1 |
cobicistat | Homo sapiens (human) | IC50 | 59.0000 | 1 | 1 |
gs-9451 | Homo sapiens (human) | IC50 | 1.4000 | 1 | 1 |
alectinib | Homo sapiens (human) | IC50 | 1.5000 | 1 | 1 |
novobiocin | Homo sapiens (human) | IC50 | 61.3939 | 5 | 5 |
dolutegravir | Homo sapiens (human) | IC50 | 48.5000 | 2 | 2 |
chir 258 | Homo sapiens (human) | IC50 | 10.3000 | 1 | 1 |
rifampin | Homo sapiens (human) | IC50 | 56.0000 | 1 | 1 |
tmc 256c1 | Homo sapiens (human) | IC50 | 12.8000 | 1 | 1 |
amg531 | Homo sapiens (human) | IC50 | 3.1000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Pyxinol bearing amino acid residues: Easily achievable and promising modulators of P-glycoprotein-mediated multidrug resistance.European journal of medicinal chemistry, , Apr-15, Volume: 216, 2021
Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Thieno[2,3-b]pyridines--a new class of multidrug resistance (MDR) modulators.Bioorganic & medicinal chemistry, , Nov-01, Volume: 22, Issue:21, 2014
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.Molecular pharmacology, , Volume: 65, Issue:6, 2004
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.Biochemical and biophysical research communications, , Jul-06, Volume: 285, Issue:1, 2001
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.Molecular pharmacology, , Volume: 65, Issue:6, 2004
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.Cancer research, , Apr-01, Volume: 64, Issue:7, 2004
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.Biochemical and biophysical research communications, , Nov-09, Volume: 288, Issue:4, 2001
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.Journal of medicinal chemistry, , 04-08, Volume: 64, Issue:7, 2021
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.ACS medicinal chemistry letters, , Apr-11, Volume: 4, Issue:4, 2013
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.Bioorganic & medicinal chemistry, , Apr-15, Volume: 15, Issue:8, 2007
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.European journal of medicinal chemistry, , Apr-05, Volume: 233, 2022
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Dec-15, Volume: 21, Issue:24, 2013
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.Molecular pharmacology, , Volume: 65, Issue:6, 2004
Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.Cancer research, , Sep-01, Volume: 63, Issue:17, 2003
A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.The Biochemical journal, , Aug-01, Volume: 373, Issue:Pt 3, 2003
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.Cancer research, , Jul-15, Volume: 63, Issue:14, 2003
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.Journal of medicinal chemistry, , 04-08, Volume: 64, Issue:7, 2021
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).European journal of medicinal chemistry, , Apr-01, Volume: 191, 2020
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.ACS medicinal chemistry letters, , Aug-09, Volume: 9, Issue:8, 2018
Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.European journal of medicinal chemistry, , Feb-15, Volume: 109, 2016
Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 23, Issue:5, 2013
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.ACS medicinal chemistry letters, , Apr-11, Volume: 4, Issue:4, 2013
Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry, , Mar-15, Volume: 19, Issue:6, 2011
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.European journal of medicinal chemistry, , Apr-05, Volume: 233, 2022
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.Journal of medicinal chemistry, , May-24, Volume: 55, Issue:10, 2012
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).European journal of medicinal chemistry, , Apr-01, Volume: 191, 2020
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.ACS medicinal chemistry letters, , Aug-09, Volume: 9, Issue:8, 2018
Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 27, Issue:20, 2017
Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization.European journal of medicinal chemistry, , Feb-15, Volume: 109, 2016
Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity.Bioorganic & medicinal chemistry letters, , 11-01, Volume: 26, Issue:21, 2016
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.ACS medicinal chemistry letters, , Apr-11, Volume: 4, Issue:4, 2013
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.Journal of natural products, , Feb-25, Volume: 74, Issue:2, 2011
Botryllamides: natural product inhibitors of ABCG2.ACS chemical biology, , Aug-21, Volume: 4, Issue:8, 2009
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.Biochemical and biophysical research communications, , Jul-06, Volume: 285, Issue:1, 2001
Interaction of AEuropean journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.Journal of medicinal chemistry, , 04-26, Volume: 61, Issue:8, 2018
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 05-25, Volume: 60, Issue:10, 2017
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).European journal of medicinal chemistry, , Oct-20, Volume: 139, 2017
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry, , Mar-15, Volume: 19, Issue:6, 2011
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.Journal of natural products, , Feb-25, Volume: 74, Issue:2, 2011
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry, , Mar-15, Volume: 19, Issue:6, 2011
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.Journal of medicinal chemistry, , 04-08, Volume: 64, Issue:7, 2021
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.Biochemical and biophysical research communications, , Jul-06, Volume: 285, Issue:1, 2001
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.European journal of medicinal chemistry, , Sep-15, Volume: 202, 2020
[no title available]Journal of medicinal chemistry, , 09-24, Volume: 63, Issue:18, 2020
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).European journal of medicinal chemistry, , Apr-01, Volume: 191, 2020
Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.European journal of medicinal chemistry, , Jan-01, Volume: 161, 2019
Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.Journal of medicinal chemistry, , 09-26, Volume: 62, Issue:18, 2019
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.Journal of medicinal chemistry, , 09-13, Volume: 61, Issue:17, 2018
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.Journal of medicinal chemistry, , 04-26, Volume: 61, Issue:8, 2018
Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 05-25, Volume: 60, Issue:10, 2017
Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).European journal of medicinal chemistry, , Oct-20, Volume: 139, 2017
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 06-09, Volume: 59, Issue:11, 2016
Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.European journal of medicinal chemistry, , Nov-29, Volume: 124, 2016
New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.European journal of medicinal chemistry, , Oct-21, Volume: 122, 2016
The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).European journal of medicinal chemistry, , Jul-19, Volume: 117, 2016
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 07-14, Volume: 59, Issue:13, 2016
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.Journal of medicinal chemistry, , Jan-08, Volume: 58, Issue:1, 2015
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.Journal of medicinal chemistry, , Jun-11, Volume: 58, Issue:11, 2015
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.Journal of medicinal chemistry, , Apr-10, Volume: 57, Issue:7, 2014
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.Journal of medicinal chemistry, , Dec-27, Volume: 56, Issue:24, 2013
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Dec-15, Volume: 21, Issue:24, 2013
Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.European journal of medicinal chemistry, , Volume: 67, 2013
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.ACS medicinal chemistry letters, , Apr-11, Volume: 4, Issue:4, 2013
4-Substituted-2-phenylquinazolines as inhibitors of BCRP.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 22, Issue:21, 2012
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.Bioorganic & medicinal chemistry, , Jan-01, Volume: 20, Issue:1, 2012
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry, , Mar-15, Volume: 19, Issue:6, 2011
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.Journal of medicinal chemistry, , Feb-26, Volume: 52, Issue:4, 2009
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.Molecular pharmacology, , Volume: 65, Issue:6, 2004
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.European journal of medicinal chemistry, , Nov-29, Volume: 124, 2016
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 07-14, Volume: 59, Issue:13, 2016
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).Journal of medicinal chemistry, , 06-09, Volume: 59, Issue:11, 2016
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).Bioorganic & medicinal chemistry, , Sep-01, Volume: 16, Issue:17, 2008
Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.Placenta, , Volume: 27, Issue:11-12
Enables
This protein enables 14 target(s):
Target | Category | Definition |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
ATP binding | molecular function | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. [ISBN:0198506732] |
organic anion transmembrane transporter activity | molecular function | Enables the transfer of organic anions from one side of a membrane to the other. Organic anions are atoms or small molecules with a negative charge which contain carbon in covalent linkage. [GOC:ai] |
ABC-type xenobiotic transporter activity | molecular function | Catalysis of the reaction: ATP + H2O + xenobiotic(in) = ADP + phosphate + xenobiotic(out). [EC:7.6.2.2] |
urate transmembrane transporter activity | molecular function | Enables the transfer of urate from one side of a membrane to the other. Urate is the anion of uric acid, 2,6,8-trioxypurine, the end product of purine metabolism in certain mammals and the main excretory product in uricotelic animals. [GOC:ai] |
biotin transmembrane transporter activity | molecular function | Enables the transfer of biotin from one side of a membrane to the other. Biotin is cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions. [GOC:ai] |
efflux transmembrane transporter activity | molecular function | Enables the transfer of a specific substance or related group of substances from the inside of the cell to the outside of the cell across a membrane. [GOC:ai, GOC:mtg_transport, ISBN:0815340729] |
ATP hydrolysis activity | molecular function | Catalysis of the reaction: ATP + H2O = ADP + H+ phosphate. ATP hydrolysis is used in some reactions as an energy source, for example to catalyze a reaction or drive transport against a concentration gradient. [RHEA:13065] |
riboflavin transmembrane transporter activity | molecular function | Enables the transfer of riboflavin from one side of a membrane to the other. Riboflavin (vitamin B2) is a water-soluble B-complex vitamin, converted in the cell to FMN and FAD, cofactors required for the function of flavoproteins. [GOC:rn, PMID:16204239] |
ATPase-coupled transmembrane transporter activity | molecular function | Primary active transporter of a solute across a membrane, via the reaction: ATP + H2O = ADP + phosphate, to directly drive the transport of a substance across a membrane. The transport protein may be transiently phosphorylated (P-type transporters), or not (ABC-type transporters and other families of transporters). Primary active transport occurs up the solute's concentration gradient and is driven by a primary energy source. [GOC:mtg_transport, ISBN:0815340729] |
identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
protein homodimerization activity | molecular function | Binding to an identical protein to form a homodimer. [GOC:jl] |
xenobiotic transmembrane transporter activity | molecular function | Enables the directed movement of a xenobiotic from one side of a membrane to the other. A xenobiotic is a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:go_curators, GOC:krc] |
sphingolipid transporter activity | molecular function | Enables the directed movement of sphingolipids into, out of or within a cell, or between cells. Sphingolipids are a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). [GOC:ai, ISBN:0198506732] |
Located In
This protein is located in 7 target(s):
Target | Category | Definition |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
apical plasma membrane | cellular component | The region of the plasma membrane located at the apical end of the cell. [GOC:curators] |
brush border membrane | cellular component | The portion of the plasma membrane surrounding the brush border. [GOC:mah] |
mitochondrial membrane | cellular component | Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope. [GOC:mah, NIF_Subcellular:sao1045389829] |
membrane raft | cellular component | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. [PMID:16645198, PMID:20044567] |
external side of apical plasma membrane | cellular component | The leaflet the apical region of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. [GOC:ab, GOC:dos] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 14 target(s):
Target | Category | Definition |
lipid transport | biological process | The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. [ISBN:0198506732] |
organic anion transport | biological process | The directed movement of organic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Organic anions are atoms or small molecules with a negative charge which contain carbon in covalent linkage. [GOC:ai, GOC:krc] |
urate transport | biological process | The directed movement of urate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:krc] |
biotin transport | biological process | The directed movement of biotin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Biotin is cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions. [GOC:ai] |
sphingolipid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). [GOC:mah, ISBN:0198506732] |
riboflavin transport | biological process | The directed movement of riboflavin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Riboflavin (vitamin B2) is a water-soluble B-complex vitamin, converted in the cell to FMN and FAD, cofactors required for the function of flavoproteins. [GOC:rn, PMID:16204239] |
urate metabolic process | biological process | The chemical reactions and pathways involving urate, the anion of uric acid, 2,6,8-trioxypurine, the end product of purine metabolism in certain mammals and the main excretory product in uricotelic animals. [ISBN:0198506732] |
transmembrane transport | biological process | The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other. [GOC:dph, GOC:jid] |
transepithelial transport | biological process | The directed movement of a substance from one side of an epithelium to the other. [GOC:mah, GOC:yaf, ISBN:0716731363] |
renal urate salt excretion | biological process | The elimination of urate salt or uric acid from peritubular capillaries (or surrounding hemolymph in invertebrates) into the renal tubules to be incorporated subsequently into the urine. [GOC:jl, PMID:25287933, PMID:3906799, Wikipedia:Renal_physiology#Secretion] |
export across plasma membrane | biological process | The directed movement of some substance from inside of a cell, across the plasma membrane and into the extracellular region. [GOC:pg] |
transport across blood-brain barrier | biological process | The directed movement of substances (e.g. macromolecules, small molecules, ions) through the blood-brain barrier. [GOC:aruk, GOC:bc, PMID:29377008] |
cellular detoxification | biological process | Any process carried out at the cellular level that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance. [GOC:vw] |
xenobiotic transport across blood-brain barrier | biological process | The directed movement of a xenobiotic through the blood-brain barrier. [PMID:25053619] |